Evidence map›Paper›PMID 42392945›Full record

ArticleClinical lymphoma, myeloma & leukemia2026

Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia.

Wei-Ying Jen, Elias Jabbour, Eitan Kugler, Nitin Jain, Rebecca Garris, Nicholas J Short, Sherry Pierce, Issa Khouri, Sa A Wang, Fadi Haddad and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wei-Ying JenDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX. Electronic address: WJen@mdanderson.org.
Elias JabbourDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Eitan KuglerDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Nitin JainDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Rebecca GarrisDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Nicholas J ShortDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Sherry PierceDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Issa KhouriDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Sa A WangDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Fadi HaddadDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Farhad RavandiDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.
Hagop KantarjianDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI REZVANI, KATY · 2003 to 2023
$43.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632
6 · The paper itself

Abstract

backgroundThe historical results in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) in second relapse treated with third-line therapy (Salvage 2) are extremely poor. Using standard chemotherapy resulted in complete response rates of 20% and a median overall survival of 2 to 3 months. This may be changing with the recent availability of novel therapeutic strategies, including targeted antibodies and engineered chimeric antigen receptor T-cell therapy, as well as more potent BCR::ABL1 tyrosine kinase inhibitors. STUDY

aimsAnalyze the outcome of adults with Ph-positive ALL with different modalities in Salvage 2. PATIENTS AND

methodsA total of 89 adults with Ph-positive ALL in Salvage 2 treated from 1992 until 2025 were analyzed.

resultsThe complete remission (CR) rate was 58%; the 3-year survival rate was 17%. By multivariate analysis, the most significant independent favorable predictors for CR and survival were the type of therapy utilized. Among 27 patients treated since 2017, the CR rate was 89% and the 3-year survival rate 52%.

conclusionsAdults with Ph-positive ALL in Salvage 2 receiving third-line therapy now have reasonable outcome expectations with the newer strategies available in the past decade.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsPhiladelphia ChromosomePrecursor Cell Lymphoblastic Leukemia-LymphomaSalvage TherapyAdolescentAdultAgedFemaleHumansMaleMiddle AgedRemission InductionTreatment OutcomeYoung AdultALL, Ph+ ALLBlinatumomabCARTInotuzumabSalvage therapy

Identifiers

PMID42392945
PMCPMC13373759

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.